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Original Article
Introduction
The 2014 National Heart Lung and Blood Institute 
(NHLBI) Expert Panel Report on the Evidence-Based 
Management of Sickle Cell Disease (SCD) was developed 
to provide “the best science-based recommendations to 
guide practice decisions.”1 In general, clinical practice 
guidelines should improve quality of care by expediting 
the application of new therapeutic advances and decreas-
ing inappropriate clinical variation. However, many barri-
ers to clinician guideline adherence have been described, 
which prevent the consistent application of guideline rec-
ommendations in everyday practice.2 Understanding such 
barriers specific to the application of the NHLBI Sickle 
Cell Disease guidelines can help those involved in guide-
line development, guideline implementation, and quality 
improvement.
We focused on 2 specific guideline recommendations 
for sickle cell anemia (SCA; which refers to HbSS or 
Hb-Sβ0-thalassemia), which are the current focus of 
quality measure development. The NHLBI guidelines 
recommend that providers “educate all patients with 
SCA and their family members about hydroxyurea 
therapy.”1(p77) The guidelines also recommend that pro-
viders “screen annually” for the risk of stroke with tran-
scranial Doppler (TCD) for children with SCA based on 
the protocol from the STOP (Stroke Prevention Trial).3 
Children with high-risk TCD should then be started on 
chronic red cell transfusions (CRCT).1(p21) Although 
both recommendations are included in the same guide-
lines, we hypothesized that since each recommendation 
focuses on a different aspect of care, there would be 
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Abstract
National guidelines recommend that providers counsel all patients with sickle cell anemia about hydroxyurea 
(HU) therapy and screen children with sickle cell anemia annually for the risk of stroke with transcranial Doppler 
(TCD). We surveyed a national convenience sample of sickle cell disease clinicians to assess factors associated with 
low adherence. Adherence was 46% for TCD screening. Low adherence was associated with a lack of outcome 
expectancy (eg, a belief that there would be poor patient follow-up to TCD testing; P < .05). Adherence was 
72% for HU counseling. Practice barriers (eg, lack of support staff or time) and a lack of agreement with HU 
recommendations were associated with low adherence (P < .05). This study demonstrates that different types of 
strategies are needed to improve TCD screening (to address follow-up and access to testing) versus HU counseling 
(to address physician agreement and practice barriers).
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different barriers to adherence that would be necessary 
to address for successful implementation.2
We conducted a cross-sectional survey of a national 
convenience sample of clinicians involved in SCD man-
agement in children to assess barriers to SCD guideline 
adherence. Understanding these barriers may provide 
insight into how to support consistent provider adher-
ence and improve the quality of SCD care.
Methods
Participants
We contacted physicians involved with the Pacific Sickle 
Cell Regional Collaborative (PSCRC) or the Dissemination 
and Implementation of Stroke Prevention: Looking at the 
Care Environment (DISPLACE) study. The PSCRC is 
composed of 15 clinical sites in the Western United States 
and is 1 of 5 regional clinical collaboratives funded by the 
US Department of Health and Human Services, Health 
Resources and Services Administration Sickle Cell Disease 
Treatment Demonstration Program. DISPLACE is a 
national multicenter study including 28 sites in the United 
States based at the Medical University of South Carolina to 
assess and improve stroke prevention implementation for 
SCD. Including providers involved in both the PSCRC and 
DISPLACE results in a broad, national convenience sam-
ple of clinicians closely involved in SCA patient care.
We excluded clinicians-in-training and clinicians who 
spent the majority of their professional time outside of 
clinical practice (ie, administration, research). Between 
January and August 2018, we sent a cover letter, an 8-page 
questionnaire, and a prepaid return envelope to each 
potential participant. We also provided access to a web-
based version of the survey. Nonrespondents received up 
to 3 reminders to complete the survey. We did not offer an 
honorarium for participation. The Committee on Human 
Research at the University of California, San Francisco, 
approved the study.
Survey Instrument
The survey instrument asked clinicians to indicate their 
level of adherence as well as barriers to adherence. The 
NHLBI Sickle Cell Disease guidelines recommend that 
patients with SCA from 2 to 16 years of age receive 
annual TCD screening and that patients with SCA who 
are ≥9 months of age be offered guidance regarding 
treatment with hydroxyurea (HU).1 Our outcome of 
interest was provider self-reported adherence to these 2 
recommendations. The latter recommendation applied 
to both adult and pediatric providers. We asked, “For 
what percentage of your patients with sickle cell anemia 
(SCA) who are ≥9 months of age do you or someone in 
your practice (nurse, colleague) offer patients/parents 
guidance regarding treatment with hydroxyurea?” In 
addition, for those providers whose practices also 
include children, we also asked, “What percentage of 
patients with SCA in your practice, ages 2 to 16 years, 
receive annual TCD measurements?”
For each of the 2 recommendations, clinicians indi-
cated their level of adherence. Respondents from 
DISPLACE sites indicated their level of adherence with 1 
of 5 possible responses: “less than half of the time” 
(<50%), “just over half of the time” (51% to 75%), “most 
of the time” (76% to 90%), “almost all of the time” (91% 
to 99%), and “all of the time” (100%). Respondents from 
PSCRC sites indicated their level adherence with 1 of 5 
possible responses: “1% to 25%,” “26% to 50%,” “51% 
to 75%,” “76% to 90%,” and “91% to 100%.”
We asked about factors associated with clinician 
guideline adherence, including access to the guideline 
(Yes/No); familiarity with the specific guideline com-
ponent (1, not at all familiar; 5, extremely familiar); 
agreement with the component (1, strongly disagree; 
5, strongly agree); and self-efficacy, which is defined 
as one’s confidence in the ability to perform the guide-
line component (1, not at all confident; 5, extremely 
confident).2 In terms of practice barriers, we asked 
about the significance of potential issues (1, not at all 
significant; 4, extremely significant), such as lack of 
equipment or clinic space, lack of time during a patient 
visit, lack of educational materials, lack of support 
staff, and lack of reimbursement for services.2
Self-efficacy was defined as the clinician’s confi-
dence in his/her ability to perform a guideline compo-
nent. Since some components might require multiple 
skills, we measured self-efficacy for each skill required 
for following each component. For the recommendation 
of TCD screening, we measured self-efficacy for 2 
skills: interpret the results of TCD screening and apply 
the results of TCD screening to guide patient manage-
ment. Self-efficacy for TCD screening was present if 
clinicians indicated that they were “very” or “extremely” 
confident for both components. For the recommendation 
of HU counseling, we measured self-efficacy for 3 
skills: recognize which patients may benefit from treat-
ment with HU, prescribe the appropriate dosage and 
schedule of HU, and recognize the side effects of treat-
ment with HU. Self-efficacy for HU counseling was 
present if clinicians indicated that they were “very” or 
“extremely” confident for all 3 components.
We asked respondents if they had concerns (none, 
slightly significant, moderately significant, or extremely 
significant) about patient TCD adherence or access to 
testing, as well as HU adherence or access. A clinician’s 
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outcome expectancy is the belief that if a recommenda-
tion is followed by the clinician, a desired outcome will 
occur (eg, improved patient outcomes). For TCD screen-
ing, lack of outcome expectancy was present if the phy-
sician indicated that they had “moderately significant” 
or “extremely significant” concerns regarding patient 
TCD adherence or access to testing. For HU counseling, 
lack of outcome expectancy was present if the physician 
indicated that they had “moderately significant” or 
“extremely significant” concerns regarding patient HU 
adherence or access.
Finally, we asked about demographic data including 
year of completion of highest level of training, practice 
setting (eg, solo, academic institution, group practice, 
federal practice, or health maintenance organization), 
academic affiliation (yes/no), number of patients with 
SCA in the clinician’s patient panel, and type of board 
certification.
Analysis
For each of the guideline recommendations, our depen-
dent variable of interest was self-reported physician 
adherence. We considered physicians as adherent if they 
reported following the guideline component >90% of 
the time, based on previous definitions of adherence.4 
For the analysis of factors associated with self-reported 
adherence, we dichotomized the responses. A factor was 
present if clinicians answered 4 or 5 on a 5-point Likert-
type scale; or 3 or 4 on a 4-point Likert-type scale. For 
example, clinicians were considered familiar with a 
guideline component if they indicated that they were 
“very” or “extremely” familiar with the component in 
question.
We used Fisher’s exact test or Student’s t test to com-
pare each of the independent variables (demographic 
characteristics, practice characteristics, and hypothe-
sized barriers to adherence) with physician self-reported 
adherence to the guideline component in question. Stata 
15.0 (StataCorp LLC, College Station, TX) was used for 
all analyses.
Results
Of the 64 eligible respondents, 43 (67%) returned our 
questionnaire. The majority (91%) of respondents cared 
for both pediatric and adult patients with SCA. 
Demographic and practice descriptions of survey 
respondents are summarized in Table 1. All respondents 
were board certified in pediatrics or internal medicine. 
Respondents had additional board certification in pedi-
atric hematology (77%), adult hematology (5%), and 
transfusion medicine (5%). The majority practiced in 
academic medical centers and had practice panels with 
more than 200 patients with SCD. The respondents were 
an experienced group of clinicians, as the mean number 
of years since training was 25 years.
Self-Reported Adherence Frequencies
Due to incomplete questionnaires, not all totals are equal 
in the analysis of each guideline component. In terms of 
self-reported adherence, 17 of 37 (46%) respondents 
reported being adherent to the TCD screening recom-
mendation. Thirty-one of 43 (72%) respondents reported 
being adherent to the HU counseling recommendation.
Guideline Awareness and Access
All 43 respondents (100%) reported having access to a 
copy of the 2014 NHLBI Sickle Cell Disease guidelines. 
Thirty-five (81%) reported being either very familiar 
(47%) or extremely familiar (35%) with the guidelines. 
Respondents learned about the guidelines by reading a 
copy (91%), attending continuing medical education 
(12%), and learning about the guideline from a physi-
cian (21%) or nonphysician colleagues (2%). Other 
Table 1. Clinician and Practice Information.
Number (%)
Practice type
 Academic medical center practice 38 (88%)
 Group private practice 2 (5%)
 Federal (military or publicly funded) 1 (2%)
 Other 2 (5%)
Number of patients with sickle cell disease
 1-20 4 (10%)
 21-100 5 (12%)
 101-200 7 (17%)
 More than 200 26 (62%)
 No response 1 (2%)
Years since completion of highest level of training (n = 42)
 1-10 years 2 (5%)
 11-20 years 14 (36%)
 21-30 years 12 (29%)
 31-40 years 12 (29%)
 More than 40 years 2 (5%)
Board certificationa
 Pediatrics 31 (72%)
 Internal medicine 4 (9%)
 Pediatric hematology 33 (77%)
 Adult hematology 2 (5%)
 Transfusion medicine 2 (5%)
aRespondents could provide multiple responses; thus, totals are 
>100%.
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sources included involvement in the development or 
review of the guidelines (12%), involvement in clinical 
trials (5%), non–continuing medical education confer-
ences (2%), other administrative work (2%), and social 
media (2%). Since respondents could indicate more than 
one answer, the totals are greater than 100%.
Barriers to TCD Adherence
Thirty-seven respondents completed all questions asso-
ciated with TCD screening practices. Table 2 describes 
the prevalence of each barrier and the association with 
TCD adherence. Overall, providers were familiar with 
(97%) and agreed (89%) with the recommendation.
Approximately one third of respondents (38%) 
reported a lack of self-efficacy in terms of interpreting 
and/or applying TCD results. Similarly, 38% of respon-
dents also reported the presence of external practice bar-
riers. The most common issue was lack of support staff. 
Seven other issues mentioned included “limited radiol-
ogy schedule” (n = 2), “obtaining accurate TCD inter-
pretations from radiologists” (n = 2), “difficulty tracking 
prior TCD results” (n = 1), “difficulty coordinating vis-
its with TCD” (n = 1), and “locations; radiology not 
close to sickle clinic” (n = 1).
The most common barrier reported was a lack of out-
come expectancy (49%). Outcome expectancy was low 
if the respondent indicated that following the recom-
mendation and ordering a TCD would be unlikely to 
affect patient outcomes (eg, due to concerns regarding 
patient access to TCD testing or due to concerns that the 
recommendation for CRCT if TCD was abnormal was 
unlikely to be followed by the patient/family). Unlike 
other barriers, the presence of this barrier was signifi-
cantly associated with nonadherence to TCD recom-
mendations (P < .05). There was no association between 
size of practice, years since training, or practice setting 
with adherence to TCD recommendations (P > .05).
Barriers to HU Adherence
Forty-three respondents completed all questions associ-
ated with HU counseling practices. Table 3 describes the 
prevalence of each barrier and the association with HU 
adherence. In general, providers were familiar with 
(93%) the recommendation.
The most common barrier was lack of self-efficacy, 
which was reported by almost half (49%) of the respon-
dents. Potential issues include recognizing which patients 
may benefit from HU (30%), prescribing the appropriate 
dose (28%), recognizing side effects (28%), or discuss-
ing the risks of the therapy with patients/families (37%). 
Almost half (44%) of respondents reported low outcome 
expectancy, which was associated with concerns about 
patient adherence to following the regimen.
Approximately one third (30%) of respondents also 
reported the presence of external practice barriers to HU 
counseling. The presence of one or more practice barriers 
was significantly associated with lack of provider adher-
ence to HU counseling recommendation (P < .05). The 
most common issue was lack of support staff (16%) to 
assist with counseling. One other issue mentioned in the 
open-ended responses included “lack of digital resources 
for distribution” (n = 1). Only 5 respondents (12%) 
Table 2. TCD Screening Barriers and Association with TCD Adherence (N = 37).
Total (N = 37) Nonadherent (n = 20) Adherent (n = 17)
Lack of familiarity with recommendation 1 (3%) 0 1
Lack of agreement with recommendation 4 (11%) 4 0
Lack of self-efficacy
 To interpret TCD results 12 (32%) 6 6
 To apply TCD results to guide therapy 8 (22%) 5 3
 To interpret or apply TCD results 14 (38%) 8 6
Lack of outcome expectancy* 18 (49%) 13 5
Presence of external barriers
 Lack of equipment or space 5 (14%) 4 1
 Lack of time 8 (22%) 5 3
 Lack of educational materials 1 (3%) 1 0
 Lack of support staff 10 (27%) 7 3
 Lack of reimbursement 2 (5%) 2 0
 Other issues 7 (19%) 4 3
 Lack of one or more of the above 14 (38%) 8 6
Abbreviation: TCD, transcranial Doppler.
*P < .05 based on Fisher’s exact test.
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indicated a lack of agreement with the HU counseling 
recommendation; however, this was associated with a 
lack of adherence to the recommendation (P < .05).
There was no association between size of practice, 
years since training, or practice setting with adherence 
to HU recommendations (P > .05).
Discussion
We systematically examined barriers to provider knowl-
edge, attitudes, and self-reported adherence to NHLBI 
guideline recommendations for TCD screening and HU 
counseling in a group of experienced providers caring 
for individuals with SCD. Self-reported adherence rates 
(defined as following recommendations for >90% of 
cases) were only 72% for HU counseling and 46% for 
TCD screening. In addition, our analysis builds on pre-
vious work, as we found that these 2 different guideline 
components have a distinctive combination of barriers 
to adherence. These findings have implications for 
developing practice interventions to more easily facili-
tate implementation of guideline-based therapies and 
SCD quality of care.
Although there were many different barriers to TCD 
screening, the one barrier significantly associated with 
low provider adherence was lack of outcome expectancy. 
In this case, low outcome expectancy was associated with 
provider concerns that even if TCD screening was ordered 
and scheduled, the likelihood of patients actually follow-
ing-up was perceived to be low or that families would be 
unlikely to commit to CRCT if TCD was abnormal. 
Additional information from open-ended questions in the 
survey describe other practice-related barriers that may 
make implementation of TCD screening and follow-up 
difficult for patients/families. Providers indicated limited 
access, proximity, or ability to coordinate patient care vis-
its for SCD with TCD examinations at radiology clinics 
as specific barriers. There were also concerns related to 
obtaining timely and accurate TCD interpretations.
These results are similar to the results of a National 
Provider Survey conducted prior to the publication of 
the 2014 guidelines. Specifically, providers reported 
that the distance to travel for testing and low patient 
adherence were barriers to TCD screening.5 Successful 
TCD screening requires multidisciplinary care, which 
can be difficult to coordinate across different settings. In 
addition, from a patient perspective, additional testing 
may require that patients go to a separate radiology cen-
ter on a different date, causing additional transportation 
burden and time away from work, which can decrease 
the likelihood of adherence.
Quality improvement methods to develop and imple-
ment a coordinated system for obtaining and improving 
the rates of initial TCD screenings for young children 
Table 3. HU Counseling Barriers and Association with HU Adherence (N = 43).
HU Counseling (N = 43) Nonadherent (n = 12) Adherent (n = 31)
Lack of familiarity with recommendation 3 (7%) 0 3
Lack of agreement with recommendation* 5 (12%) 4 1
Lack of self-efficacy
 To recognize which patients may benefit from HU 13 (30%) 6 7
 To prescribe appropriate dose and schedule of HU 12 (28%) 6 6
 To recognize side effects of HU 12 (28%) 6 6
 To discuss risk of possible HU side effects with 
patients/parents
16 (37%) 7 9
 To at least one of the above (eg, recognize which 
patients may benefit, prescribe HU, recognize side 
effects, or discuss HU risk)
21 (49%) 8 13
Lack of outcome expectancy 19 (44%) 7 12
Presence of external barriers
 Lack of equipment or space 3 (7%) 2 1
 Lack of time 6 (14%) 2 4
 Lack of educational materials 6 (14%) 3 3
 Lack of support staff* 7 (16%) 5 2
 Lack of reimbursement 5 (12%) 3 2
 Other issues 1 (2%) 0 1
 Lack of one or more of the above* 13 (30%) 7 6
Abbreviation: HU, hydroxyurea.
*P < .05 based on Fisher’s exact test.
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have been used and documented in a large health care 
system.6 Incorporation of TCD screening within com-
prehensive SCD clinics during a comprehensive visit 
may be another strategy to improve patient adherence, 
outcomes, and satisfaction.7 However, this approach 
may require a significant patient panel size to be cost-
effective or practical.
Improving parent/family understanding of the impor-
tance of TCD screening and initiation of CRCT may 
help improve patient/family engagement and thus pro-
vider outcome expectancy regarding TCD screening. 
Interviews with families suggested that improving 
knowledge about the purpose of TCD screening and 
greater empowerment may help improve annual TCD 
follow-up.8 In addition, the use of personalized remind-
ers to families and additional information about screen-
ing have been used as a quality improvement intervention 
to increase the rate of TCD screening.9
For HU counseling, we found that low adherence 
was associated with lack of provider agreement with 
the recommendation. In 2008, a survey of health care 
providers noted that lack of awareness and lack of 
agreement regarding HU benefits was associated with 
HU underprescribing.10 Although lack of awareness 
was less common in our current study, the presence of 
lack of agreement still seems to be associated with poor 
HU recommendation adherence. Previously reported 
provider concerns about HU include the potential carci-
nogenic issues, doubts about HU clinical effectiveness, 
and potential adverse effects.11
Interventions to address issues with provider agree-
ment include endorsement by local opinion leaders or 
specialty societies.12,13 Opinion leaders are defined as 
members of a local community who influence the com-
munity acceptance of new ideas or therapies, such as a 
guideline.12 Providers tend to adhere to guidelines devel-
oped by their own specialty organization.13 The American 
Academy of Pediatrics and the American Society of 
Hematology endorsed the NHLBI SCD guidelines in 
2014.14,15 As a result, emphasizing the endorsement of 
these guidelines by pediatric or internal medicine profes-
sional societies might improve guideline agreement by 
pediatricians and internists, respectively.
The presence of practice barriers, such as the lack of 
support staff, was also associated with low HU counsel-
ing. Patients and families may have a variety of different 
medication concerns (eg, potential side effects, overuse 
of medications), which are closely associated with long-
term HU medication adherence.16 As a result, it can be 
challenging to educate, counsel, and coach patients 
regarding chronic medications during the limited time of 
an outpatient visit. The presence of additional support 
staff can help improve clinic efficiency. In addition, 
there are interventions and counseling techniques that 
have been used to help improve clinician counseling and 
education efficacy for patients with chronic disease.17
Limitations
The survey was conducted with a convenience sample of 
SCD providers from the United States, who do not repre-
sent a random, national sample of SCD providers. These 
providers are likely to be more interested and involved in 
SCD clinical trials and/or work at clinics more likely to 
be tailored for SCD treatment. As a result, the likelihood 
of practice barriers may be even higher in a more general 
sample. We relied on provider self-report of adherence, 
which might not reflect actual practice. However, our 
purpose was to investigate if different SCD guideline 
recommendations are associated with different barriers. 
Even if self-report overestimates adherence, it is unlikely 
to affect the relationships of the types of barriers associ-
ated with nonadherence. In addition, the fact that 12% of 
the respondents reported being involved in the develop-
ment or review of the NHLBI guidelines is concerning, 
as these respondents may be biased in terms of following 
the guidelines. However, despite this limitation, which 
may inflate guideline adherence, there was still a low rate 
of adherence to TCD screening for SCD (46%), as well 
at the relatively low rate (72%) for HU counseling.
In addition, another limitation is the terminology used 
in describing how HU should be discussed with families. 
The guidelines state that providers should “educate” 
about HU therapy, but the guidelines further describe 
some specific topics that should be “counseled” (eg, not 
to double up on doses). In our survey instrument, we 
asked physicians how often they “offer patients/parents 
guidance regarding treatment with hydroxyurea.” 
Although the terms “educate,” “counsel,” and “offer 
guidance” all suggest different aspects of shared deci-
sion-making, the lack of a single, concise term to capture 
the recommendation could lead to different interpreta-
tions of the action by the respondents and different esti-
mates of how often the action occurs in practice.
Finally, we can only report on a respondents’ percep-
tion of the barrier, which may not be an accurate reflec-
tion of how problematic or prevalent a barrier is. 
However, our goal was to also help identify potential 
interventions to improve adherence. Whether the prob-
lem is actual or perceived may also affect the type of 
intervention needed to overcome the barrier.
Implications
In conclusion, although providers seem to be well 
aware of the existence of the NHLBI SCD guidelines, 
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there are many barriers to their successful use. These 
results have implications for selecting interventions to 
improve SCD practice. Interventions should be tai-
lored to the guideline recommendation being 
addressed. For example, the factors associated with 
adherence to HU counseling suggest a need to address 
provider agreement with the recommendation, as well 
as methods to improve HU counseling during the 
clinic visit. To improve TCD screening, this study sug-
gests that improving parent/family understanding of 
the importance of TCD and making TCD screening 
more accessible and coordinated with SCD visits may 
be the most important issues associated with guideline 
adherence.
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